Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
26 March 2021Website:
http://www.edgewisetx.comNext earnings report:
21 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 21 Nov 2024 23:19:05 GMTDividend
Analysts recommendations
Institutional Ownership
EWTX Latest News
Edgewise Therapeutics NASDAQ: EWTX is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks.
Edgewise Therapeutics NASDAQ: EWTX is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive hypertrophic cardiomyopathy did remarkably well in early trials.
Edgewise stock soars on positive data from an early-stage study and Part A of a mid-stage study of EDG-7500 in obstructive hypertrophic cardiomyopathy patients.
On Thursday, Edgewise Therapeutics Inc. EWTX released announced topline data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial for obstructive hypertrophic cardiomyopathy.
Edgewise Therapeutics develops small molecules for myopathies, with lead molecule sevasemten in phase 3 for Becker Muscular Dystrophy. Company was founded in 2017, backed by OrbiMed, with an experienced management team and strong financials. Sevasemten offers a genotype-agnostic approach, competitive difference from dystrophin-targeting therapies, with potential high market valuation.
Does Edgewise Therapeutics, Inc. (EWTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
The consensus price target hints at a 52.8% upside potential for Edgewise Therapeutics, Inc. (EWTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 33.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 70.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Edgewise (EWTX) will issue secondary shares to raise $240 million in gross proceeds. The capital will be used to fund key initiatives, including the potential commercial launch of lead pipeline drugs.
What type of business is Edgewise Therapeutics?
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
What sector is Edgewise Therapeutics in?
Edgewise Therapeutics is in the Healthcare sector
What industry is Edgewise Therapeutics in?
Edgewise Therapeutics is in the Biotechnology industry
What country is Edgewise Therapeutics from?
Edgewise Therapeutics is headquartered in United States
When did Edgewise Therapeutics go public?
Edgewise Therapeutics initial public offering (IPO) was on 26 March 2021
What is Edgewise Therapeutics website?
https://www.edgewisetx.com
Is Edgewise Therapeutics in the S&P 500?
No, Edgewise Therapeutics is not included in the S&P 500 index
Is Edgewise Therapeutics in the NASDAQ 100?
No, Edgewise Therapeutics is not included in the NASDAQ 100 index
Is Edgewise Therapeutics in the Dow Jones?
No, Edgewise Therapeutics is not included in the Dow Jones index
When was Edgewise Therapeutics the previous earnings report?
No data
When does Edgewise Therapeutics earnings report?
The next expected earnings date for Edgewise Therapeutics is 21 February 2025